All In MedTech

Device Trial Radar · NCT06743113

Hypoxic Red Blood Cells in Sickle Cell Anemia

A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Apr 1, 2029

Study completion Oct 1, 2029

Sponsor

Lead sponsor
HemanextNot on our public-company list
Sponsor type
Industry
Collaborators
Emory University; University of Connecticut; University of Pittsburgh Medical Center; Johns Hopkins University; University of Illinois Chicago; National Heart, Lung, and Blood Institute (NHLBI)
First posted
Dec 19, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.

Conditions

  • Sickle Cell Anaemia
  • Sickle Cell Anemia Crisis
  • Sickle Cell Anemia in Children
  • Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Interventions

  • Hemanext ONE SystemDevice

    Hypoxic red blood cells

  • Conventional RBCsDevice

    Conventional red blood cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. %HbA Rate of DeclineTime frame: Through study completion, an average of 14 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • New England Sickle Cell Institute, University of Connecticut

    Farmington, Connecticut

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Illinois at Chicago

    Chicago, Illinois

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.